ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is
more effective than best supportive care alone, for the treatment of patients with non-small
cell lung cancer, whose disease has recurred after previous chemotherapy and an Epidermal
Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI). ZD6474 is a new anti-cancer drug
in development that works in a different way to standard chemotherapy drugs. It targets the
growth of new blood vessels to a tumour and thereby might slow the rate at which the tumour
may grow. Early studies indicate that ZD6474 has a positive effect on the time that a tumour
may take to progress to a further stage. Approximately 930 patients will take part in this
study. It will be conducted in hospitals and clinics in North and South America, Europe and
Asia.